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Abstract
Background: Isolated local recurrence after surgical resection for pancreatic cancer is rare. Current common therapies for recurrence include chemotherapy 
or chemoradiation. There are few, if any, reports regarding surgical resection of local pancreatic cancer recurrence. This is the first report of using irreversible 
electroporation (IRE) to treat a pancreatic adenocarcinoma local recurrence and represents a true 5-year survivor and possible cure. 
Case report: A 50-year-old female initially presented with 2.5 cm mass in the uncinate process of the pancreas suspicious for malignancy. Preoperative endoscopic 
guided fine needle aspirate (FNA) confirmed adenocarcinoma. She underwent pylorus preserving pancreaticoduodenectomy with the finding of stage II pancreatic 
cancer with complete resection after neoadjuvant chemotherapy. One year later she developed recurrent abdominal pain and restaging scans confirmed a new 2.5 
cm lesion in the retroperitoneum. Positron emission tomography (PET) scan confirmed local recurrence. No metastatic disease was identified. She subsequently 
underwent chemotherapy and radiation therapy with persistent mass lesion present. After a period of stability, she was taken for laparotomy with IRE of the entire 
retroperitoneal tumor, followed by adjuvant chemotherapy. She has been closely monitored with computed tomography (CT) scans and tumor markers. Her most 
recent scan confirmed complete resolution of the lesion. She is now over 6 years from pancreaticoduodenectomy with no additional signs of pancreatic cancer 
recurrence.
Conclusions: Patients with isolated recurrent pancreatic cancer are uncommon and have limited treatment options. IRE is currently used for locally-advanced, 
unresectable pancreatic cancer with promising results. This case serves as an example that IRE can contribute to enhanced long term survival for patients with 
pancreatic adenocarcinoma, including those with isolated local recurrence.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer death in 
men and women in the United States [1]. Although there are only about 
50,000 new cases of pancreatic cancer cases a year, the mortality rate 
is very high. Five-year survival rates in the US for local, regional and 
metastatic disease are 29%, 11%, and 3% [1]. Local recurrence after 
surgical resection is around 30%, and there are limited modalities for 
treatment once the patient reaches this point [2]. Chemotherapy or 
chemoradiation has become standard of care after pancreatic cancer 
local recurrences. Surgical resection was also recently shown to have 
a favorable survival outcome in resectable isolated local recurrent 
pancreatic cancer, but further studies are warranted [3].
Advances in ablative therapies over the past two decades allow 
patients to have another possible option of treatment for locally 
advanced pancreatic cancer (LAPC) or locally recurrent pancreatic 
cancer. Thermal ablative therapies include radiofrequency ablation 
(RFA) and microwave ablation (MWA), while non-thermal ablative 
therapies include irreversible electroporation (IRE). Thermal ablation 
is a poor treatment modality for tumors located close to vital structures, 
such as vessels, bowel, or ducts, which is why the IRE technology 
has gained popularity with pancreatic head tumors. This emerging 
technology uses electrodes to deliver short, pulsed currents to create 
nanoscopic pores in cell membranes of tumor cells, which causes 
cell death or apoptosis. IRE has been proven to be feasible for tumor 
ablation in the liver, pancreas and prostate, while efficacy in organs such 
as the lung and kidney have not been substantially proven [4]. 
This is the first reported case of a patient with locally recurrent 
pancreatic cancer after chemotherapy and surgical resection who 
was subsequently treated with multi-modality therapy, including 
irreversible electroporation (NanoKnife; AngioDynamics; Queensbury, 
NY, USA) and is now a true 5-year survivor, and possible cure.
Case presentation
This is a 50 year-old Caucasian female with past medical history 
of gastroesophageal reflux and tobacco use (17 pack years) who 
presented initially in 2010 with complaints of epigastric and right 
upper quadrant pain radiating to her back. Initial work up included 
esophagogastroduodenoscopy (EGD), right upper quadrant ultrasound, 
and HIDA scan which were normal, except for esophagitis and gastritis. 
Due to worsening pain, she underwent an abdominal CT scan in March 
2010 which showed a 2.5 cm ill-defined mass located in the pancreatic 
uncinate process (Figure 1). Her exam was unremarkable. Laboratory 
results showed normal liver enzymes, bilirubin, amylase, lipase, 
but an elevated CA 19-9 of 451. Patient was enrolled in the clinical 
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trial ACOSOG Z5041 where she received 3 cycles of neoadjuvant 
chemotherapy (gemcitabine and erlotinib). This was a phase II trial that 
addresses the benefit of erlotinib as an adjunct to gemcitabine during 
the perioperative setting for resectable pancreatic cancer. 
The patient underwent a pylorus preserving Whipple procedure in 
July 2010. Intraoperatively there was no evidence of metastatic disease. 
The tumor was firm and palpable in the uncinate process and extended 
up to the fatty tissue in the retroperitoneum next to the superior 
mesenteric artery (SMA). The SMA was ultimately skeletonized to 
resect the tumor with R0 resection. Tumor was 1 cm in size with grade 3 
chemotherapy effect, <10% viable tumor cells. No vascular invasion was 
noted. Pathology confirmed 16 negative lymph nodes, and all margins 
were negative. Three cycles of postoperative chemotherapy per trial 
protocol. Follow up consisted of physical exam, CT scans, labs every 
3-4 months for the first year, and every 4-6 months after.
She did well for the next year, but developed recurrent abdominal 
pain in May 2011. Abdominal CT scan demonstrated a new lesion in 
the retroperitoneum at previously placed clip (Figure 2). Endoscopic 
ultrasound (EUS) with biopsy showed a 2.5 cm mass, but was 
inaccessible for biopsy. PET scan confirmed significant uptake with 
SUV of 9.2 in this area only. She then completed four more cycles of 
chemotherapy (gemcitabine and oxaliplatin), and received radiation. 
On repeat abdominal CT scan in October 2011, the lesion decreased in 
size to 2 cm, but did not resolve.
Due to residual mass lesion present in December 2011, an 
exploratory laparotomy with IRE of the area of recurrent pancreatic 
cancer was planned. A solitary small nodule, about 2 cm in size, was 
palpated and confirmed by ultrasound to be on the SMA anterior to 
the IVC and was penetrated by the main branches of the SMV. The 
nodule was deemed unresectable. The decision was then made to ablate 
the nodule with the Nanoknife. Three needles were used to create a 
triangular field. In determining optimal tissue ablation in this patient, 
we placed the needles 1.5 cm apart and performed 1.5 cm exposure and 
applied 90 pulses per cycle between 2 needles. Ultrasound confirmed 
placement and changes of the nodule within placement. There was no 
replacement of the needles, but a single pull back of the needles to allow 
adequate coverage of the entire lesion.
Follow up imaging showed post-operative inflammatory changes 
which are expected after IRE. Repeat imaging was performed at 1 
month, 3 months, and then at 3-4 month intervals over the next 2 years 
with eventful resolution of the mass lesion. Most recent imaging is 
showing in (Figure 3). Tumor markers are also checked regularly and 
returned to normal and currently remain within normal ranges. She 
continues to be followed routinely. 
Discussion
Ablative therapies (thermal and nonthermal) have emerged as 
innovative treatment options for locally advanced pancreatic cancer 
(LAPC), but are also able to be utilized for locally recurrent disease. 
Thermal ablation techniques have significant limitations due to risk of 
damaging vital structures. Radiofrequency ablation (RFA) causes tissue 
destruction through high frequency alternating currents generating 
high local temperatures (>40°C) which cause a coagulative necrosis 
[5]. Risks of RFA therapy include thermal injury to nearby vasculature, 
bowel and biliary tree which leads to complications such as portal 
vein thrombosis, duodenal injury and gastrointestinal bleeding [6,7]. 
Microwave ablation (MWA) is another treatment modality for LAPC. 
A generator uses microwave energy via an antenna to heat the desired 
tissue and cause coagulative necrosis. The frequency range of MWA 
compared to RFA allows a better predictable ablation volume [6]. A 
case series with 15 patients with LAPC concluded no major procedure 
related morbidity and mortality. Most common complications were 
minor and include mild pancreatitis, asymptomatic hyperamylasemia, 
pancreatic ascites, and minor bleeding [8]. Further long-term studies 
are needed to determine survival benefit of MWA despite early results 
of low patient morbidity in this small patient population. 
In contrast, nonthermal ablative techniques such as irreversible 
electroporation (IRE) could be used for pancreatic tumors that are near 
vessels and vital structures, which made it an ideal choice for our patient 
with a tumor closely located near the IVC, portal vein, or SMA [5]. The 
device works by applying short, pulsed, high-voltage electrical currents 
across a cell which leads to non-reversible poration, the formation of 
nanopores in the cell membrane, which causes apoptosis of the cell 
[9]. Only the lipid bilayer of the cell membrane is affected with IRE, 
which is in contrast to thermal ablation where all the molecules are 
affected [6]. IRE can be used percutaneously with imaging guidance, 
laparoscopically, or through an open approach. Probes are positioned 
Figure 1. CT imaging of primary pancreatic adenocarcinoma (March 2010)
Figure 2. Recurrence of pancreatic adenocarcinoma (May 2011)
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parallel to one another at an ideal spacing of 2 cm from one another 
to ensure complete electroporation of the target, however pancreatic 
tissue frequently requires adjustment of exposure and spacing to 
accommodate tissue penetration [10].
Due to the mechanism of action targeting the cell membrane only, 
IRE has been successfully demonstrated safe ablation in liver porcine 
models without negatively affecting nearby blood vessels and bile ducts 
[11]. A pilot study used IRE ablation in vivo in the pancreas of porcine 
models to successfully show histological evidence of irreversible 
ablation as soon as 2 hours post procedure without signs of pancreatitis 
or pancreatic duct injury [12]. The unique characteristics of not 
injuring nearby blood vessels or ducts allows IRE to be the modality of 
choice to treat tumors within close approximation to vital structures in 
comparison to other ablation techniques. There is also no loss of heat 
secondary to convection (“heat sink effect”) which leads to incomplete 
ablation as documented with thermal ablation techniques [9].
Limitations of IRE include the need for general anesthesia and 
tumor size. General anesthesia with complete muscle paralysis is 
necessary to counteract the stimulation of skeletal muscles with the 
high voltage delivered to the probes and to prevent muscle contraction 
from moving the position of the probes [9]. The optimal size of locally 
advanced pancreatic cancer is less than 3 cm for new users, and less 
than 4 cm for experienced users [10]. Our patient’s presentation with 
recurrent pancreatic cancer was 2 cm in size and within these limits. 
Contraindications for IRE include history of cardiac arrhythmia, recent 
myocardial infarction, and nearby vicinity to devices with metal parts 
(such as metal biliary stent). IRE pulse delivery is synchronized with 
the patient’s electrocardiogram to minimize risk of cardiac event. 
Arrhythmias are contraindicated because the pulses are unable to be 
synchronized with the R-waves [9]. Metallic stents may conduct the 
electrical current and deflect the energy causing damage to surrounding 
structures or incomplete ablation [13]. Pre-operative removal of these 
stents is advisable.
Extensive research about LAPC and IRE has been performed by 
Martin et al. A prospective evaluation of long term effects of IRE on 
liver and pancreatic locally advanced carcinoma showed that the IRE 
attributable morbidity rate was 13.3%, with only 4.19% high grade 
complications seen, such as bleeding, biliary complications and DVT/
PE being most common. Although pancreatic lesions were more likely 
to have complications than liver lesions, the safety profile was similar 
to other studies. Local recurrence rate was 23%, with median time for 
pancreatic recurrence was 16 months [14].
Previous treatment options for patients with unresectable or locally-
recurrent pancreatic cancer were solely limited to chemotherapy or 
chemoradiation therapy. The comparison of IRE patients who received 
at least 4 months of neoadjuvant chemo to standard treatment of 
adjuvant chemotherapy showed a statistically significant improvement 
in local progression-free survival, distant progression-free survival 
and overall survival [15]. Due to IRE only targeting the local disease, 
pre-operative and post-operative chemotherapy with or without 
chemoradiation is still administered to attempt to control potential 
undetected distant lesions as was performed in our patient.
Martin et al proposed a clinical usage algorithm for IRE in patients 
with locally advanced stage III pancreatic adenocarcinoma, which may 
be able to be applied to locally recurrent pancreatic tumors as well. They 
recommend precise staging with triple phase CT scan and diagnostic 
laparoscopy with peritoneal washings to accurately discern stage III 
local disease with a sub-radiologically occult stage IV patient [10]. At 
least four months of induction chemotherapy is then completed, with 
repeat imaging after chemotherapy to ensure there is no progression of 
disease. At this time, definitive local therapy or palliative procedures 
may be performed, which is where IRE may be applicable.
Uses for IRE technology in pancreatic cancer currently include 
therapy for unresectable locally advanced pancreatic cancer, and 
margin accentuation during surgical resection [10]. The application 
of this technology can potentially be expanded to locally-recurrent 
pancreatic cancer near vital structures if the patient is found to be a 
suitable candidate.
Conclusion
Most research for IRE in pancreatic cancer involves its use with 
unresectable stage III locally advanced disease. There is a paucity of data 
regarding its use with locally recurrent pancreatic cancer after surgical 
resection. Therapy in these patients is inherently limited. Though 
conclusions are obviously limited based on this single case report, IRE 
can be considered in this patient population in combination with the 
standard treatment of chemotherapy or chemoradiation. Further studies 
or series will be needed before we can identify a true survival advantage.
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